Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | KDM5A | P29375 | 7/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432233 | 1.00 | PARP1 (0.54) | PARP1KDM5AKDM5BKDM4EACHE | |
| SCHEMBL31139842 | 0.88 | KDM5A (0.57) | PARP1KDM5AKDM5BKDM4ECSNK1A1 | |
| SCHEMBL25430812 | 0.88 | KDM5A (0.57) | PARP1KDM5AKDM5BKDM4ECSNK1A1 | |
| SCHEMBL13818064 | 0.85 | KDM5A (0.57) | PARP1KDM5AKDM5BKDM4EACHE | |
| SCHEMBL29612172 | 0.78 | KDM4E (0.69) | PARP1KDM4EDAO | |
| SCHEMBL19952775 | 0.78 | KDM4E (0.69) | PARP1KDM4EDAO | |
| SCHEMBL25431584 | 0.77 | PADI4 (0.56) | — | |
| SCHEMBL25431587 | 0.77 | PADI4 (0.56) | — | |
| SCHEMBL31139794 | 0.77 | PADI4 (0.56) | — | |
| SCHEMBL30590387 | 0.77 | PADI4 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | PARP1 51/4885KDM5A 3184/4885KDM5B 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.